Maresin-2 Fine-tunes ULK1 O-GlcNAcylation to Improve Post Myocardial Infarction Remodeling

Jingjing Zhang, Chenyu Li, Yanzhao Wei, Shujuan Jiang, Xiaolin Wu, Qing Zhou, Shuang Yang, Hu He, He Huang, Bin Kong, Wei ShuaibioRxiv 2023 · DOI

TL;DR

This study reveals a novel mechanism by which maresin-2, an anti-inflammatory mediator, protects the heart after myocardial infarction. Maresin-2 promotes autophagy by fine-tuning the O-GlcNAcylation of ULK1, a key protein in initiating this cellular cleanup process, offering a new therapeutic avenue for cardiac repair.

What Problem Does This Paper Address?

Myocardial infarction (MI) is a major cause of mortality, and while the body attempts to repair the damaged heart, this process is complex and often leads to adverse remodeling. Inflammation plays a critical role in this cascade, and specialized pro-resolving mediators (SPMs) like maresin-2 are known to fine-tune inflammatory responses. However, the precise molecular mechanisms by which maresin-2 exerts its protective effects, particularly in the context of cardiac repair and autophagy, remained largely unknown. This paper aims to elucidate how maresin-2 influences cardiac function and remodeling post-MI, focusing on its potential role in modulating autophagy.

Methods

The researchers employed a multi-pronged approach combining in vivo and in vitro techniques. Key methods included:

  • Genome Editing: CRISPR-Cas9 technology was used to create genetically modified mice (e.g., Alox12 knockout mice) to investigate the role of endogenous maresin-2.
  • Molecular Biology Techniques: Western blotting was extensively used to assess protein expression levels, including key players in autophagy (LC3, p62, ULK1 complex components) and signaling pathways (e.g., p-ULK1, p-AMPK, p-mTORC1).
  • Cellular Assays:
    • Autophagosome Formation: Assessed using transmission electron microscopy (TEM) and fluorescent reporters (mRFP-GFP-LC3II).
  • O-GlcNAcylation: Investigated using immunoprecipitation assays to detect O-GlcNAc modifications on ULK1.
  • Hexosamine Biosynthesis Pathway (HBP) Analysis: Measured UDP-GlcNAc and related metabolite levels using LC-MS.
  • Animal Models: Standard models for myocardial infarction were established, including LAD ligation (Type I MI) and isoproterenol injection (Type II MI).
  • Cardiac Function Assessment: Echocardiography was performed to evaluate left ventricular ejection fraction (LVEF), fractional shortening (LVFS), and chamber dimensions.
  • Histological Staining: Hematoxylin-eosin (HE) and Sirius Red staining were used to assess myocardial injury and fibrosis.
  • Immunofluorescence: Used to visualize specific proteins and cellular structures.
  • Electrophysiology: Recorded neural activity from the LSG.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Maresin-2 as a Cardiac Protector: The study strongly suggests that maresin-2 plays a significant role in protecting the heart from damage and adverse remodeling following myocardial infarction.
  • ULK1 O-GlcNAcylation is Key: The central finding is that maresin-2 modulates the O-GlcNAcylation of ULK1, a crucial initiator of autophagy, thereby enhancing this cellular repair mechanism.
  • GFAT1 as a Central Hub: Maresin-2 appears to activate GFAT1, a rate-limiting enzyme in the hexosamine biosynthesis pathway, which in turn increases UDP-GlcNAc availability for O-GlcNAcylation.
  • Inhibition of TAK1-TAB1 Pathway: Maresin-2 suppresses the TAK1-TAB1 inflammatory signaling complex, which seems to free up TAB1 to interact with and activate GFAT1. This highlights a novel cross-talk between inflammation and O-GlcNAcylation.
  • Specific O-GlcNAcylation Sites: The study identifies Ser409 and Ser422 on ULK1 as potential O-GlcNAcylation sites that are critical for maresin-2's effect on autophagy.

Key Results

  • Improved Cardiac Function: Maresin-2 treatment in MI mice led to improved cardiac diastolic parameters and ameliorated cardiac hypertrophy, as evidenced by reduced cardiomyocyte cross-sectional area.
  • Enhanced Autophagy: Maresin-2 dose-dependently increased ULK1 complex expression and LC3-II formation, indicating enhanced autophagosome formation.
  • Increased HBP Flux: Maresin-2 treatment resulted in a twofold increase in UDP-GlcNAc concentration and fueled glutamine consumption, pointing to increased hexosamine biosynthesis.
  • Suppression of Inflammatory Signaling: Maresin-2 suppressed TAK1/IKKs/NF-κB phosphorylation, reducing pro-inflammatory cytokines like IL-1β and TNF-α.
  • ULK1 O-GlcNAcylation: Maresin-2 treatment led to increased O-GlcNAcylation of ULK1, particularly at Ser409 and Ser422, which was essential for its pro-autophagic effects. Mutating these sites impaired maresin-2's ability to induce autophagic flux.

Limitations and Future Work

  • Structural Validation: While Ser409 and Ser422 are identified as key O-GlcNAcylation sites, the paper notes that structural analysis (e.g., X-ray crystallography or cryo-EM) is needed to definitively understand how these sites interact and contribute to O-GlcNAcylation.
  • Interplay with NF-κB: The complex interplay between O-GlcNAcylation and the NF-κB pathway, including the extent to which O-GlcNAc modification of NF-κB subunits interferes with ULK1 O-GlcNAcylation, requires further investigation.
  • Therapeutic Potential: While the findings are promising for cardiac repair, further research is needed to translate these findings into clinical applications. The paper suggests that maresin-2 could serve as a therapeutic agent for myocardial infarction.

Summary updated

Abstract

Abstract Maresin-2, a specialized pro-solving mediator of inflammation has been consolidated to be a novel cytokine fine-tuning inflammatory cascade. However, the underlying molecular basis is still largely unknown. Focused on cardiac dysfunction and remodeling, we employed in vivo- and in vitro- based genome editing methodology tools including adenosine associated virus, adenosine virus, lenti-virus, plasmid transfection, and CRISPR-Cas9 methodology for investigation. As suggested, exogenous maresin-2 supplement facilitated autophagosome formation by microtubule-associated proteins 1A/1B light chain 3B (LC3) conjugation system under the modulation of O-GlcNAcylation dependent ULK1 activation, whereas reversed by ULK1 S409A and S422A mutagenesis, showcasing the potential O-GlcNAc (O-linked β- N-acetylglucosamine) modifiable sites on ULK1. Moreover, we found that hereafter maresin-2 treatment glutamine-fructose-6-phosphate aminotransferase 1 (GFAT1) which is accessary to sense hexosamine biosynthesis influx is more likely the prime checkpoint for conjugating O-terminal β-N-acetylglucosamine motif onto ULK1, rather than O-linked N-acetylglucosaminyltransferase (OGT). Mechanistically, maresin-2 largely prohibits transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1), therefore increasing the availability of TAB1 for GFAT1, which encourages O-GlcNAcylation of ULK1.
BibTeX
@misc{zhang2023maresin,
  author = {Jingjing Zhang and Chenyu Li and Yanzhao Wei and Shujuan Jiang and Xiaolin Wu and Qing Zhou and Shuang Yang and Hu He and He Huang and Bin Kong and Wei Shuai},
  title = {{Maresin-2 Fine-tunes ULK1 O-GlcNAcylation to Improve Post Myocardial Infarction Remodeling}},
  year = {2023},
  doi = {10.1101/2023.07.16.549182},
  howpublished = {bioRxiv},
}
Figure